AUS
NZ
UK
CA
USA
IND
Highlights
- Radiopharm Theranostics has increased its stake in Radiopharm Ventures from 75% to 87.5%.
- Radiopharm Ventures was established in partnership with MD Anderson Cancer Center in 2022.
- Lead candidate Betabart has received US FDA IND clearance for a Phase I therapeutic trial, the first global trial targeting B7H3.
- First patient dosing for Betabart is expected in Q1 2026.
- Two additional preclinical programs show early promise, progressing toward final candidate selection.
Radiopharm Theranostics Limited (ASX:RAD) has increased its ownership stake in Radiopharm Ventures, LLC from 75% to 87.5%, strengthening its position in the joint venture established with The University of Texas MD Anderson Cancer Center (MDACC). The move comes as the venture continues to make encouraging progress across its cancer therapeutics pipeline, including advances in its lead B7H3 program and other preclinical assets.
Lead B7H3 Candidate Advances to Clinical Stage
The joint venture’s leading asset, Betabart (RV01), is a monoclonal antibody radiolabelled with Lutetium-177 that targets the immune checkpoint protein B7H3. Betabart received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration in July 2025 for a Phase I therapeutic trial in multiple solid tumors.
The first patient is expected to be dosed in the first quarter of 2026, with several clinical trial sites already activated. The program represents the first global clinical trial targeting B7H3 using a systemic radiopharmaceutical approach.
B7H3: A Target Linked to Cancer Progression
B7H3 is minimally expressed in healthy tissues but is consistently overexpressed in a wide range of cancer types. Elevated B7H3 expression has been associated with increased tumour size and lymphatic invasion, making it a promising target for therapeutic intervention.
Additional Assets Show Early Promise
Beyond Betabart, Radiopharm Ventures is progressing two additional preclinical programs that have demonstrated early positive results. These assets are advancing toward final candidate selection, with development milestones planned during 2026 and potential application across multiple solid tumour indications.
Strategic Collaboration with MDACC
Radiopharm Ventures was formed in 2022 to develop novel radiopharmaceutical therapies targeting cancers with high unmet medical need. The venture combines MD Anderson’s expertise in antigen discovery and molecular imaging with Radiopharm’s capabilities in developing targeted radiopharmaceutical therapies.
RAD shares were trading at AUD 0.024 per share at the time of writing on 12 January 2026.
